Blue­print met all its end­points in bid for ex­pand­ed Ay­vak­it la­bel — but stock trends low­er any­way

3 years ago
R&D

No­var­tis-part­nered biotech nabs new cash, boost­ing ef­forts to de­vel­op 'func­tion­al cure' for chron­ic he­pati­tis B

3 years ago
Financing

Pres­i­dent Biden signs ma­jor drug pric­ing re­forms in­to law: What's com­ing for bio­phar­ma?

3 years ago
Pharma
Law

Up­dat­ed: EU­'s lend­ing arm grants Pol­ish biotech $22M+ in debt fi­nanc­ing to ad­vance pipeline

3 years ago
Financing

A cou­ple bil­lion for Ex­sci­en­tia was on­ly part of Sanofi's AI am­bi­tions, as the Big Phar­ma adds Atom­wise to the ta­ble

3 years ago
Deals
AI

Squeezed by As­traZeneca/Dai­ichi Sankyo, biotech de­vel­op­ing HER2 ADC switch­es CEO, launch­es pipeline re­view

3 years ago
People
R&D

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

3 years ago
R&D

Ab­b­Vie calls off PhI tri­al for I-Mab’s CD47 days af­ter Zai Lab shelves its own pro­gram

3 years ago
R&D
Pharma

Bris­tol My­ers gets nec­es­sary clear­ance for $4.1B Turn­ing Point ac­qui­si­tion

3 years ago
Deals
R&D

Bill & Melin­da Gates Foun­da­tion dou­bles down on health part­ner­ship with South Ko­rea — re­port

3 years ago
Pharma

Zan­tac lit­i­ga­tion: One suit down, many more to go, GSK says

3 years ago
Law

HHS in­spec­tor gen­er­al: NIH failed to ver­i­fy clin­i­cal tri­al re­sults were re­port­ed on time

3 years ago
Pharma
FDA+

More than a decade af­ter its ac­cel­er­at­ed ap­proval, vot­ing ques­tions set for pre­ma­ture birth drug's with­draw­al hear­ing

3 years ago
Pharma
FDA+

As­traZeneca files law­suit against for­mer ex­ec as he jumps to GSK

3 years ago
People
Pharma

What’s in mon­key­pox names? His­to­ry, tra­di­tion­al con­ven­tion and even sit­com sug­ges­tions

3 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Ho­log­ic taps fa­mous singer again for women’s health screens; HIV drug mak­ers pitch in to raise ...

3 years ago
Pharma
Marketing

FDA grants pri­or­i­ty re­view to Lyn­parza com­bo ther­a­py for metasta­t­ic prostate can­cer

3 years ago
R&D
Pharma

Ho­mol­o­gy lays off staff, paus­es rare meta­bol­ic dis­ease tri­al de­spite clin­i­cal hold lift

3 years ago
R&D

Pos­i­tive read­out? Pub­lic of­fer­ing: Virid­i­an plans to raise $175M on eye dis­ease ther­a­py da­ta

3 years ago
Financing
R&D

Roche’s Po­livy con­tin­ues its reg­u­la­to­ry dance, will head to FDA for a form of blood can­cer

3 years ago
R&D
Pharma

TYK2 heats up with Ven­tyx eye­ing mid-stage tri­als; Nex­Im­mune cites com­pe­ti­tion in pipeline cull

3 years ago
News Briefing

Gos­sip in Baby­lon: Dig­i­tal health com­pa­ny paints M&A ru­mors as flat-out wrong

3 years ago
Financing
Deals

New Hahn-era texts show the ex­tent of the Trump White House­'s in­volve­ment in vac­cine EUA process

3 years ago
FDA+
Coronavirus

Buy­ing time to catch up on sales, ADC Ther­a­peu­tics takes on $175M loan

3 years ago
Financing
First page Previous page 472473474475476477478 Next page Last page
A service from the Financial Times